Up-to-date approach in diagnosis and treatment of primary mediastinal B-cell lymphoma

Olivera Marković; Zorica Cvetković; Ilija Bukurecki; Anica Divac; Nataša Stanisavljević; Milena Todorović-Balint; Bela Balint

doi:10.2298/VSP241015013M

Olivera Marković *Clinical Hospital Center “Bežanijska kosa”, Clinic for Internal Medicine, Department of Hematology, Belgrade, Serbia; †University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Zorica Cvetković University of Belgrade, Faculty of Medicine, Belgrade, Serbia; ‡University Hospital Medical Center “Zemun”, Clinic for Internal Medicine, Department of Hematology, Belgrade, Serbia
Ilija Bukurecki *Clinical Hospital Center “Bežanijska kosa”, Clinic for Internal Medicine, Department of Hematology, Belgrade, Serbia
Anica Divac *Clinical Hospital Center “Bežanijska kosa”, Clinic for Internal Medicine, Department of Hematology, Belgrade, Serbia
Nataša Stanisavljević *Clinical Hospital Center “Bežanijska kosa”, Clinic for Internal Medicine, Department of Hematology, Belgrade, Serbia; †University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Milena Todorović-Balint †University of Belgrade, Faculty of Medicine, Belgrade, Serbia; §University Clinical Center of Serbia, Clinic for Hematology, Belgrade, Serbia
Bela Balint Serbian Academy of Sciences and Arts, Department of Medical Sciences, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP241015013M

Keywords: antineoplastic combined chemotherapy protocols;, biomarkers;, diagnosis;, gene expression;, histological techniques;, lymphoma, large b-cell, diffuse;, prognosis;, tomography, emission-computed

Author Biography

Olivera Marković, *Clinical Hospital Center “Bežanijska kosa”, Clinic for Internal Medicine, Department of Hematology, Belgrade, Serbia; †University of Belgrade, Faculty of Medicine, Belgrade, Serbia

Department of Hematology

References

Camus V, Drieux F, Jardin F. State of the art in the diagnosis, biology and treatment of primary mediastinal B-cell lympho-ma: a review. Ann Lymphoma 2022; 6: 13.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Or-ganization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36(7): 1720–48. Erra-tum in: Leukemia 2023; 37(9): 1944–51.

Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, et al. Integrative genomic analysis identifies key patho-genic mechanisms in primary mediastinal large B-cell lympho-ma. Blood 2019; 134(10): 802–13.

Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, d'Amore ES, Szczepanowski M, et al. Clinical, pathological and genetic fea-tures of primary mediastinal large B-cell lymphomas and medi-astinal gray zone lymphomas in children. Haematologica 2011; 96(2): 262–8.

Savage KJ. Primary mediastinal large B-cell lymphoma. Blood 2022; 140(9): 955–70.

Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 2016; 101(5): 531–40.

Abramson JS, Palomba ML, Gordon LI, Lunning M, Wang M, Arnason J, et al. Two-year follow-up of lisocabtagene mara-leucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 2024; 143(5): 404–16.

Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Ba-lakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 2017; 130(3): 267–70.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with brentuximab vedotin for re-lapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the Phase II CheckMate 436 Study. J Clin Oncol 2019; 37(33): 3081–9.

Jovanović MP, Jaković Lj, Bogdanović A, Marković O, Martinović VC, Mihaljević B. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells. Vojnosanit Pregl 2009; 66(9):738–43.

Markovic O, Marisavljevic D, Cemerikic V, Perunicic M, Savic S, Filipovic B, et al. Clinical and prognostic significance of apop-totic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). Eur J Haematol 2011; 86(3): 246–55.

Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or re-fractory primary mediastinal large B-cell lymphoma: final anal-ysis of KEYNOTE-170. Blood 2023; 142(2): 141–45. Erra-tum in: Blood 2024; 143(13): 1316.

Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123(13): 2062–5.

Forlenza CJ, Chadburn A, Giulino-Roth L. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults. J Natl Compr Canc Netw 2023; 21(3): 323–30.

Zhou H, Xu-Monette ZY, Xiao L, Strati P, Hagemeister FB, He Y, et al. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J 2020; 10(5): 49.

Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Martinovic T, Filipovic B, Stanisavljevic D, et al. Survivin expression in pa-tients with newly diagnosed nodal diffuse large B cell lym-phoma (DLBCL). Med Oncol 2012; 29(5): 3515–21.

Markovic O. Risk-stratification in diffuse large B-cell lympho-ma in the rituximab era. Med Pregl 2022; 75(Suppl 1): 82–7.

Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, et al. Comparison of prognostic impact of ab-solute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur J Intern Med 2014; 25(3): 296–302.

Vassilakopoulos TP, Michail M, Papageorgiou S, Kourti G, Angelo-poulou MK, Panitsas F, et al. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. Oncologist 2021; 26(7): 597–609.

Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic bi-omarkers associated with outcome. Am J Hematol 2016; 91(10): E436–41.

Noerenberg D, Briest F, Hennch C, Yoshida K, Hablesreiter R, Takeuchi Y, et al. Genetic Characterization of Primary Medias-tinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes. J Clin Oncol 2024; 42(4): 452–66.

Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, et al. Outcomes after first-line immunochemotherapy for pri-mary mediastinal B-cell lymphoma: a LYSA study. Blood Adv 2021; 5(19): 3862–72.

Ceriani L, Martelli M, Conconi A, Zinzani PL, Ferreri AJM, Botto B, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Br J Haematol 2017; 178(4): 588–91.

Schroers-Martin JG, Kurtz DM, Soo J, Jin MC, Scherer F, Craig AFM, et al. Determinants of circulating tumor DNA levels across lymphoma histologic subtypes. Blood 2017; 130: 4018.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol 2018; 36(28): 2845–53.

Hayden AR, Tonseth P, Lee DG, Villa D, Gerrie AS, Scott DW, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood 2020; 136(24): 2803–11.

Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 368(15): 1408–16.

Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in front-line management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol 2018; 180(4): 534–44. Erratum in: Br J Haematol 2018; 181(1): 152.

Santarsieri A, Bennett R, Hopkins D, Lewis KL, Gyansah CN, Cooke L, et al. R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation. Blood 2022; 140(Supplement 1): 9551–3.

Malenda A, Kołkowska-Leśniak A, Puła B, Długosz-Danecka M, Chełstowska M, et al. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol 2020; 104(1): 59–66.

Iannitto E, Balzarotti M, Martelli M, Zinzani P, Tucci A, Di Rocco, et al. Primary Mediastinal B-cell Lymphoma, a nationwide re-al-life retrospective study from Fondazione Italiana Linfomi (FIL). Hematol Oncol 2023; 41: 408–10.

Rieger M, Österborg A, Pettengell R, White D, Gill D, Walewski J, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011; 22(3): 664–70.

Moskowitz C. R-CHOP-14 Followed by ICE Consolidation without Radiation Therapy for Primary Mediastinal B-Cell Lymphoma (PMBCL). Presentation discussed in this issue: Sequential dose dense R-CHOP followed by ICE consolida-tion (MSKCC protocol 01-142) without radiotherapy for pa-tients with primary mediastinal B cell lymphoma [Internet]. Proc ASH 2010; Abstract 420 [accessed on 2024 Dec 26]. Available from: https://www.researchtopractice.com/index.php?q=br

owse-tumor-types/heme/5mjc_ash/22

Gleeson M, Hawkes EA, Cunningham D, Chadwick N, Counsell N, Lawrie A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol 2016; 175(4): 668–72.

Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol 2017; 179(5): 739–47.

Halahleh K, Yaseen A, Muradi I, Al-Ibraheem A, Sultan I, Ma'koseh M. Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP. Ј Blood Med 2023; 14: 147–57.

Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, et al. Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients. Ann Hematol 2021; 100(9): 2261–8.

Cook MR, Williams LS, Dorris CS, Luo Y, Makambi K, Dunlea-vy K. Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients. Haematologica 2024; 109(3): 846–56.

Jackson MW, Rusthoven CG, Jones BL, Kamdar M, Rabinovitch R. Improved survival with radiation therapy in stage I-II primary mediastinal B cell lymphoma: a surveillance, epidemiology, and end results database analysis. Int J Radiat Oncol Biol Phys 2016; 94(1): 126–32.

Giri S, Bhatt VR, Pathak R, Bociek RG, Vose JM, Armitage JO. Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: a US population-based analysis. Am J Hematol 2015; 90(11): 1052–4.

Ceriani L, Martelli M, Gospodarowicz MK, Ricardi U, Ferreri AJ, Chiappella A, et al. Positron emission tomography/computed tomography assessment after immunochemotherapy and irra-diation using the Lugano classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma. Int J Radiat Oncol Biol Phys 2017; 97(1): 42–9.

Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinza-ni PL, et al. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediasti-nal B-cell lymphoma. Blood 2018; 132(2): 179–86.

Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, et al. Positron emission tomography-computed tomogra-phy predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv 2018; 2(11): 1334–43.

Zucca E, Davies A, Kryachok I, Ciccone G, Ceriani L, Botto B, et al. Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard im-munochemotherapy: The IELSG37 randomized trial. J Clin Oncol 2023; 41(17¬_suppl): LBA7505.

Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, et al. Outcomes of relapsed and refractory primary medi-astinal (Thymic) large B cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant 2018; 24(10): 2133–8.

Aoki T, Shimada K, Suzuki R, Izutsu K, Tomita A, Maeda Y, et al. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma. Blood Cancer J 2015; 5(12): e372.

Avivi I, Boumendil A, Finel H, Nagler A, Bothello AS, Santasusa-na JM, et al. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma in the rituximab era: a retrospec-tive study by the EBMT Lymphoma Working Party. Blood 2014; 124(21): 1195.

Kuruvilla J, Armand P, Hamadani M, Kline J, Moskowitz CH, Avi-gan D, et al. Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leuk Lymphoma 2023; 64(1): 130–9.

Michot JM, Armand P, Ding W, Ribrag V, Christian B, Marinello B, et al. KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS). Ann Oncol 2016; 27: viii15.

Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective re-sponses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015; 125(9): 1394–402.

Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023; 141(19): 2307–15.

Svoboda J, Bair SM, Landsburg DJ, Dwivedy Nasta S, Nagle SJ, Barta SK, et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica 2021; 106(6): 1705–13.

Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 2024; 109(4): 1184–93.

Kim SJ, Yoon DH, Kang HJ, Hong JY, Lee HS, Oh Sy, et al. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer 2019; 19(1): 1080.